Cochrane · systematic review · CD011367
Intravenous immunoglobulin for the treatment of childhood encephalitis
Iro, MA, Martin, NG, Absoud, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intravenous immunoglobulin with or without standard care compared with standard care alone or placebo for children with acute encephalitis
Population: children with acute encephalitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant disability assessed using Liverpool Outcome Score RR (M‐H, random‐effects analysis, 95% CI) Intravenous immunoglobulin with or without standard care vs standard care alone or placebo | RR 0.75 [0.22, 2.6] | 1 study · 22 participants | Very low Downgraded: risk of bias |
≥ 1 serious adverse event RR (M‐H, random‐effects analysis, 95% CI) Intravenous immunoglobulin with or without standard care vs standard care alone or placebo | RR 1 [0.07, 14.05] | 1 study · 22 participants | Very low Downgraded: risk of bias |
Length of hospital stay (MD, random‐effects analysis, 95% CI) Intravenous immunoglobulin with or without standard care vs standard care alone or placebo | no estimate extracted | 2 studies · 116 participants | Very low Downgraded: risk of bias, imprecision, indirectness |